Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Clinical Cancer Research
JournalCitation impact & published research
Clinical Cancer Research is a journal indexed in ScholarIQ from OpenAlex. ScholarIQ records 27,687 works, 1,646,710 citations and an h-index of 421.
27,687
Works
1,646,710
Citations
421
h-index
IDs:OpenAlex
What are the most-cited papers on Clinical Cancer Research?
ScholarIQmost cited works
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
Torsten O. Nielsen, Forrest D. Hsu, Kristin C. Jensen, Maggie C.U. Cheang, Gamze Karaca, Zhiyuan Hu, Tina Hernandez‐Boussard, Chad Livasy, Dave Cowan, Lynn G. Dressler, Lars A. Akslen, Joseph Ragaz, Allen M. Gown, C. Blake Gilks, Matt van de Rijn, Charles M. Perou
Clinical Cancer Research. 20042,664 CitationsOPEN ACCESS
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers
Helena A. Yu, Maria E. Arcila, Natasha Rekhtman, Camelia S. Sima, Maureen F. Zakowski, William Pao, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Gregory J. Riely
Clinical Cancer Research. 20132,497 CitationsOPEN ACCESS
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg, James Chih‐Hsin Yang, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Giao Q. Phan, Deborah E. Citrin, Nicholas P. Restifo, Paul F. Robbins, John R. Wunderlich, Kathleen E. Morton, Carolyn M. Laurençot, Seth M. Steinberg, Donald E. White, Mark E. Dudley
Clinical Cancer Research. 20112,135 CitationsOPEN ACCESS
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Lisa A. Carey, Elizabeth Claire Dees, Lynda Sawyer, Lisa Gatti, Dominic T. Moore, Frances A. Collichio, David W. Ollila, Carolyn I. Sartor, Mark L. Graham, Charles M. Perou
Clinical Cancer Research. 20072,122 CitationsOPEN ACCESS
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, Xiujun Fu, Christopher G. Azzoli, Zofia Piotrowska, Tiffany G. Huynh, Ling Zhao, Linnea Fulton, Katherine R. Schultz, Emily Howe, Anna F. Farago, Ryan J. Sullivan, James R. Stone, Subba R. Digumarthy, Teresa Morán, Aaron N. Hata, Yukako Yagi, Beow Y. Yeap, Jeffrey A. Engelman, Mari Mino–Kenudson
Clinical Cancer Research. 20161,254 CitationsOPEN ACCESS
Related on ScholarIQ
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
Paper
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers
Paper
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Paper
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Paper
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Paper
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Paper